qwertyuiopasdfghjklzxcvbnmqwerty

uiopasdfghjklzxcvbnmqwertyuiopasd
fghjklzxcvbnmqwertyuiopasdfghjklzx
cvbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmqwertyuiopasdfghjklzxc
vbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
NIFTY OUTLOOK
hjklzxcvbnmqwertyuiopasdfghjklzxc
REPORT
vbnmqwertyuiopasdfghjklzxcvbnmq
th
30 May 2017
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmrtyuiopasdfghjklzxcvbn
mqwertyuiopasdfghjklzxcvbnmqwert
yuiopasdfghjklzxcvbnmqwertyuiopas
 30th May 2017

NIFTY

NIFTY SPOT : R1:9630 R2:9675 R3:9699

PIVOT : 9596 S1:9552 S2:9520 S3:9400

NIFTY DAILY CHART

NIFTY OUTLOOK
Nifty is likely to open in a negative note up to 30 points. Momentum indicators are indicating towards a weak
trading session today. Positional traders are advised to keep their long hold with a stop loss of 9650.While
intraday traders are advised to short nifty around 9600 with a stop loss of 9630 for the target of 9550.

Strategy: Short Nifty around 9600-9610 with a stop loss of 9650 for the target of 9540.

Name Current Value Change % Chg Open High Low

FTSE 100 (May 26) 7,547.63 29.92 0.4 7,517.71 7,554.21 7,514.39
CAC 40 (May 29) 5,332.47 -4.17 -0.08 5,327.73 5,335.78 5,316.69
DAX (May 29) 12,628.95 26.77 0.21 12,588.80 12,633.37 12,578.58
Nikkei 225 (May
19,614.50 -68.07 -0.35 19,681.11 19,681.11 19,570.13
30)
Straits Times (May
3,201.77 -12.78 -0.4 3,215.71 3,215.71 3,200.80
30)
Hang Seng (May
25,701.63 62.36 0.24 25,672.40 25,744.72 25,579.15
29)

Taiwan Weighted 10,101.95 -6.54 -0.06 10,090.18 10,121.88 10,072.84

(May 26)
SGX Nifty (May
9,589.00 -28 -0.29 9,623.00 9,623.00 9,577.50
30)

WWW.EQUITYRESEARCHLAB.COM
 30th May 2017

CORPORATE NEWS & Mahindra, Hindalco Industries, REC, United Spirits, Berger Paints, SAIL,
Results today: Mahindra
Vakrangee, Apollo Hospital

-Lyka Labs announces outlicensing deal with US based Generics company

-Network 18 Media & Investments in focus: ICRA upgraded rating to AAA to long-term borrowings
of Rs 500 crore

-Astrazeneca Pharma received import and market permission in Form 45 (marketing authorisation)
from the Drug Controller General of India for Osimertinib tablet 40 mg and 80 mg

-Syndicate Bank approved to raise equity capital up to Rs 3,500 crore

-Veto Switchgear inaugurated its manufacturing plant (100 percent export unit) at light engineering
zone, Mahindra SEZ, Jaipur

-Vikas Ecotech approves scheme for demerger of the recycled compounds and trading division

-Bhushan Steel, Videocon, Jaiprakash Associates, JSPL, Alok Industries in focus: Government
turns focus on 50 top stressed loan accounts

-Mindtree to add 1400 employees in Bhubaneshwar

-TeamLease to buy 30 percent stake in Freshworld

WWW.EQUITYRESEARCHLAB.COM
 30th May 2017

ERL RESEARCH TEAM

Member Name Designation E-mail ID

Mr. Tuhinanshu Jain Research Head Tuhinanshu.jain@equityresearchlab.co.in
Mr. Manish Bimal Sr. Research Analyst Manish.bimal@equityresearchlab.co.in

DISCLAIMER

The information and views in this report, our website & all the service we provide are believed to be
reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have
the right to choose the product/s that suits them the most. Investment in Stocks has its own risks.
Sincere efforts have been made to present the right investment perspective. The information contained
herein is based on analysis and up on sources that we consider reliable. We, however, do not vouch
for the accuracy or the completeness thereof. This material is for personal information and we are not
responsible for any loss incurred based upon it & takes no responsibility whatsoever for any financial
profit s or loss which may arise from the recommendations above. The stock price projections shown
are not necessarily indicative of future price performance. The information herein, together with all
estimates and forecasts, can change without notice.

Equity Research Lab does not purport to be an invitation or an offer to buy or sell any financial
instrument. Analyst or any person related to Equity Research Lab might be holding positions in the
stocks recommended. It is understood that anyone who is browsing through the site has done so at his
free will and does not read any views expressed as a recommendation for which either the site or its
owners or anyone can be held responsible for. Any surfing and reading of the information is the
acceptance of this disclaimer.

Our Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our
calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly
or indirectly by them. If found so then Serious Legal Actions can be taken. Any surfing and reading of
the information is the acceptance of this disclaimer.

ALL RIGHTS RESERVED.

WWW.EQUITYRESEARCHLAB.COM